"Prime [Therapeutics]' proposal was highly competitive and will deliver high-quality care at lower costs."

— Kerry Bendel, chief pharmacy officer at Regence Blue Cross and Blue Shield plans, on the insurer's decision to move its PBM contract from UnitedHealth Group PBM OptumRx to Prime